Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.49 |
| ▸ | LPL | P06858 | 7/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 4/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933637 | 0.91 | LIPG (0.56) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL19794354 | 0.87 | DGAT1 (0.53) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL20696492 | 0.86 | DGAT1 (0.47) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL19933583 | 0.85 | DGAT1 (0.55) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL21390525 | 0.84 | LIPG (0.50) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL23487738 | 0.84 | LIPG (0.67) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL19933666 | 0.82 | TGFBR1 (0.45) | WNT3ATGFBR1HSD17B1HSD17B2CYP11B1 | |
| SCHEMBL29293266 | 0.81 | LIPG (0.71) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL21390496 | 0.80 | DGAT1 (0.43) | DGAT1LIPGLPLPDGFRBKDR | |
| SCHEMBL20696470 | 0.80 | DGAT1 (0.43) | DGAT1LIPGLPLPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507294-B1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | MERCK PATENT GMBH | 2021-01-12 | — | — | US | disclosed |
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-07-04 | — | — | US | disclosed |
| WO-2018041769-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | PARN, PUF60, PARG | DGAT1 2586/4885LIPG 4374/4885LPL 4558/4885 |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | PARN, PUF60, PARG | DGAT1 2586/4885LIPG 4374/4885LPL 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.